In the course of searching for bioactive secondary metabolites from marine fungi, TMC-256C1 was isolated from an ethyl acetate extract of the marine-derived fungus Aspergillus sp. SF6354. TMC-256C1 displayed anti-neuroinflammatory effect in BV2 microglial cells induced by lipopolysaccharides (LPS) as well as neuroprotective effect against glutamate-stimulated neurotoxicity in mouse hippocampal HT22 cells. TMC-256C1 was shown to develop a cellular resistance to oxidative damage caused by glutamate-induced cytotoxicity and reactive oxygen species (ROS) generation in HT22 cells, and suppress the inflammation process in LPS-stimulated BV2 cells. Furthermore, the neuroprotective and anti-neuroinflammatory activities of TMC-256C1 were associated with upregulated expression of heme oxygenase (HO)-1 and nuclear translocation of nuclear factor-E2-related factor 2 (Nrf2) in HT22 and BV2 cells. We also found that TMC-256C1 activated p38 mitogen-activated protein kinases (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways in HT22 and BV2 cells. These results demonstrated that TMC-256C1 activates HO-1 protein expression, probably by increasing nuclear Nrf2 levels via the activation of the p38 MAPK and PI3K/Akt pathways.
Introduction
Oxidative stress and neuroinflammation are associated with disorders of the central nervous system (CNS) [1] . Oxidative stress overexpression of reactive oxygen species (ROS) can induce neural injury and thus contribute to the progression of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), resulting in neuronal death and malfunction [2] .
Glutamate, a main neurotransmitter in the CNS, plays a critical role in neurodegenerative diseases such as AD, PD, and Huntington's disease [3] . Many studies have been conducted on glutamate-induced cytotoxicity in HT22 cell lines, an immortalized mouse hippocampal cell line lacking ionotropic glutamate receptors [4] . Neuroinflammation is a crucial mechanism underlying neuronal damage within the brain in neurodegenerative diseases including AD, PD, and amyotrophic lateral sclerosis [5, 6] . Microglia, considered as macrophage in the brain, play a crucial role in immune defense in the central nervous system (CNS). Once stimulated, microglia produce inflammatory mediators including nitric oxide (NO), tumor necrosis factor-α (TNF-α), and prostaglandin E 2 (PGE 2 ) [7, 8] . The BV2 cell line is considered to represent brain macrophages and is mainly used as a model of neuroinflammation [9] [10] [11] . In this study, mouse hippocampal HT22 cells and BV2 cells were used to examine the neuroprotective and anti-neuroinflammatory effects of certain secondary metabolites from nature.
Heme oxygenase (HO)-1 is a stress-responsive enzyme induced by stimulants including heat shock, oxidants and heavy metals. HO-1 plays a role as a catalyst for the degradation of heme groups, producing carbon monoxide, biliverdin, and free iron [12, 13] . Heme and these metabolites play important roles in the regulation of several biological responses such as oxidative damage, cell injury, and inflammation. According to its anti-oxidative effects, HO-1 is recognized as a target for the therapy of inflammatory diseases [14, 15] . It has been reported that HO-1 provides the anti-inflammatory action by suppressing the production of pro-inflammatory cytokines and chemokines such as TNF-α, IL-1β, IL-6, and MIP-1β in activated macrophages. In addition, HO-1 and its by-products suppress the expression of pro-inflammatory mediators such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), leading to decreases in the production of NO and PGE 2 [16, 17] .
The expression of HO-1 is regulated by nuclear transcription factor erythroid-2 related factor 2 (Nrf2), a main regulator of detoxifying/antioxidant phase II enzymes such as HO-1. Nrf2 binds to specific DNA sequences such as the anti-oxidant response element present in the promoter regions of phase II enzymes, and increases their transcription [18] . Recently, natural products such as curcumin, resveratrol, and flavonoids have been reported to show protective effects on neuronal damage induced by oxidative stress through the induction of HO-1 [19] [20] [21] .
Marine-derived fungi have been regarded as promising sources of metabolites with diverse structures and bioactivities, and some metabolites from marine fungi have inspired the development of new classes of drugs [22] [23] [24] . In the course of our ongoing search for bioactive secondary metabolites from marine-derived fungi, TMC-256C1, a napthopyranone derivative [25] was isolated from marine-derived fungal strain Aspergillus sp. SF6354, and was found to exhibit cytoprotective and anti-inflammatory effects.
In this report, the isolation, structure elucidation, and bioactivity of TMC-256C1 are presented. Furthermore, the molecular mechanisms involved in the cytoprotective and anti-neuroinflammatory effects of TMC-256C1 were investigated.
Results

Structure Determination and Isolation of TMC-256C1, and Effect of TMC-256C1 on the Viability of HT22 and BV2 Cells
To identify the bioactive TMC-256C1 in the organic extract of culture media of the marine fungus Aspergillus sp. SF-6354, several purification methods were employed, including flash column chromatography and high performance liquid chromatography (HPLC), leading to the isolation of a napthopyrone fungal metabolite, TMC-256C1 ( Figure 1A ). The structure of the isolated TMC-256C1 was identified by analysis of nuclear magnetic resonance spectroscopy (NMR) and mass spectrometry (MS) data, along with comparison of its spectral data to those reported in the literature [26] . To evaluate the cytotoxic effect of TMC-256C1, we evaluated its effect on the viability of BV2 ( Figure 1B ) and HT22 cells ( Figure 1C ). MTT assay performed at 5-40 µM of TMC-256C1 revealed no cytotoxic effects in either HT22 or BV2 cells.
Effects of TMC-256C1 on Glutamate-Induced Cytotoxicity and Reactive Oxygen Species Generation
At non cytotoxic concentrations (5-40 µM), we examined whether TMC-256C1 exerted cytoprotective effects and reactive oxygen species (ROS) scavenging activity against glutamate-induced cytotoxicity and ROS generation by treating HT22 cells with glutamate (5 mM) for 12 h (Figure 2A,B) . Application of glutamate to the cells led to increased ROS production; however, pre-incubation (3 h) with TMC-256C1 effectively suppressed this induction ( Figure 2B ). Trolox ® is a well-known anti-oxidative agent, and was used as a positive control, showing a significant cytoprotective effect and ROS scavenging activity at the concentration of 40 µM. 
At non cytotoxic concentrations (5-40 μM), we examined whether TMC-256C1 exerted cytoprotective effects and reactive oxygen species (ROS) scavenging activity against glutamateinduced cytotoxicity and ROS generation by treating HT22 cells with glutamate (5 mM) for 12 h (Figure 2A,B) . Application of glutamate to the cells led to increased ROS production; however, pre-incubation (3 h) with TMC-256C1 effectively suppressed this induction ( Figure 2B ). Trolox ® is a well-known anti-oxidative agent, and was used as a positive control, showing a significant cytoprotective effect and ROS scavenging activity at the concentration of 40 μM. Figure 2 . Effects of TMC-256C1 on glutamate-induced oxidative neurotoxicity (A); and generation of reactive oxygen species (B). HT22 cells were treated with TMC-256C1 and then incubated for 12 h with glutamate (5 mM) (A). Exposure of HT22 cells to glutamate resulted in increased reactive oxygen species production (B). Data are presented as the mean value of three experiments ± SD. * p < 0.05 compared to the group treated with glutamate. Trolox ® (50 μM) was used as a positive control. +  +  +  +  +  +  -Glutamate  +  +  +  +  +  +   ------+  Trolox  ------+  Trolox   ---5  2 0  10  TMC-256C1 (μM)  40  ---5  2 0  10  TMC-256C1 ( 
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Effects of TMC-256C1 on Pro-Inflammatory Cytokines in BV2 Cells Stimulated with Lipopolysaccharides (LPS)
To further evaluate the anti-neuroinflammatory effects of TMC-256C1 on lipopolysaccharides (LPS)-stimulated BV2 cells, the mRNA expression levels of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6 and IL-12 were evaluated in the both presence and absence of TMC-256C1 at non-cytotoxic concentrations (5-40 µM). BV2 cells were pretreated with TMC-256C1 for 3 h, followed by stimulation with LPS (1 µg/mL) for 12 h. As shown in Figure 3 , LPS treatment triggered a significant increase in the mRNA expression levels of pro-inflammatory cytokines in the culture media, compared to those of the untreated group. However, pre-treatment of the cells with TMC-256C1 for 3 h significantly decreased the mRNA expression levels of TNF-α, IL-6 and IL-12 in a dose-dependent manner, but had little or no inhibitory effect on the mRNA expression of IL-1β. 
To further evaluate the anti-neuroinflammatory effects of TMC-256C1 on lipopolysaccharides (LPS)-stimulated BV2 cells, the mRNA expression levels of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6 and IL-12 were evaluated in the both presence and absence of TMC-256C1 at non-cytotoxic concentrations (5-40 μM). BV2 cells were pretreated with TMC-256C1 for 3 h, followed by stimulation with LPS (1 μg/mL) for 12 h. As shown in Figure 3 , LPS treatment triggered a significant increase in the mRNA expression levels of pro-inflammatory cytokines in the culture media, compared to those of the untreated group. However, pre-treatment of the cells with TMC-256C1 for 3 h significantly decreased the mRNA expression levels of TNF-α, IL-6 and IL-12 in a dose-dependent manner, but had little or no inhibitory effect on the mRNA expression of IL-1β. 
Effects of TMC-256C1 on the Protein Expression Levels of Inducible Nitric Oxide Synthase (iNOS) and Cyclooxygenase-2 (COX-2) in BV2 Cells Stimulated with LPS
We also investigated the effects of TMC-256C1 on LPS-induced NO and PGE2 production as well as iNOS and COX-2 protein expression in BV2 cells (Figure 4 ). BV2 cells were challenged with LPS 1 μg/mL) in the presence or absence of TMC-256C1 at non-cytotoxic concentrations (5-40 μM). re-treatment of the cells with TMC-256C1 for 3 h resulted in a decreased concentration of iNOS-derived NO ( Figure 4A ) and iNOS expression ( Figure 4C ). Under the same conditions, TMC-256C1 also suppressed COX-2 expression ( Figure 4C ) and was also found to reduce COX-2-derived PGE2 production ( Figure 4B ). Our results showed that TMC-256C1 suppressed the 
We also investigated the effects of TMC-256C1 on LPS-induced NO and PGE 2 production as well as iNOS and COX-2 protein expression in BV2 cells ( Figure 4 ). BV2 cells were challenged with LPS 1 µg/mL) in the presence or absence of TMC-256C1 at non-cytotoxic concentrations (5-40 µM). re-treatment of the cells with TMC-256C1 for 3 h resulted in a decreased concentration of iNOS-derived NO ( Figure 4A ) and iNOS expression ( Figure 4C ). Under the same conditions, TMC-256C1 also suppressed COX-2 expression ( Figure 4C ) and was also found to reduce COX-2-derived PGE 2 production ( Figure 4B ). Our results showed that TMC-256C1 suppressed the LPS-induced production of inflammatory mediators (i.e., NO and PGE 2 ) via suppression of iNOS and COX-2 protein expression.
LPS-induced production of inflammatory mediators (i.e., NO and PGE2) via suppression of iNOS and COX-2 protein expression. Figure 4 . Effects of TMC-256C1 on the production of NO (A) and PGE2 (B) and the protein expression levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) (C) in BV2 cells stimulated with LPS. Cells were pre-treated for 3 h with the indicated concentrations of TMC-256C1, and for 24 h with LPS (1 μg/mL). Western blot analysis (C) was performed as described in the Experimental Section. Band intensity was quantified by densitometry and normalized to β-actin, and the normalized values are presented at the bottom of each band. Data represent the mean values of three experiments ± SD. * p < 0.05 compared to the group treated with LPS.
Effects of TMC-256C1 on NF-κB Activation in BV2 Cells Stimulated with LPS
Therefore, in order to elucidate the mechanisms underlying the anti-neuroinflammatory effects of TMC-256C1, we examined the effects of TMC-256C1 on the phosphorylation and degradation of IκB-α by Western blot analysis. As shown in Figure 5 , IκB-α was phosphorylated and degraded after the cells were treated with LPS for 1 h, however, the phosphorylation and degradation of IκB-α were markedly suppressed by pre-treatment of the cells with TMC-256C1 (10-40 μM) for 3 h ( Figure 5A ). In accordance with this, the levels of nuclear NF-κB p65 and p50 in BV2 cells were increased after the cells were treated with LPS for 1 h, while the levels were decreased in response to pretreatment of TMC-256C1 (10-40 μM) in the LPS-stimulated cells in a dose-dependent manner ( Figure 5B ). In addition, LPS pre-treatment (1 h) led to an increased DNA-binding activity of NF-κB in nuclear extracts of BV2 cells; however, TMC-256C1 inhibited the DNA-binding activity of NF-κB in LPS-stimulated cells in a dose-dependent manner ( Figure 5C ). This observation suggested that TMC-256C1 inhibited the LPS-induced nuclear translocation of NF-κB (p65 and p50) through preventing the phosphorylation and degradation of IκB. 
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Figure 5. Effects of TMC-256C1 on LPS-induced NF-κB activation (A-C).
Following pretreatment with TMC-256C1 (10, 20, and 40 μM) for 3 h, cells were treated with LPS for 1 h. Total proteins were prepared and Western blot analysis was performed using antibodies specific for IκB-α and p-IκB-α (A); Cytosolic and nuclear extracts were prepared for use in Western blots for NF-κB p65 and p50, using specific anti-p65 and anti-p50 monoclonal antibodies (B); A commercially available NF-κB ELISA (Active Motif) was used to test the nuclear extracts and determine the degree of NF-κB binding (C). Band intensity was quantified by densitometry and normalized to β-actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and proliferating cell nuclear antigen (PCNA), and the normalized values are presented at the bottom of each band. The data shown, representative of three independent experiments, are the mean values of three experiments ± SD. * p < 0.05 compared to the group treated with LPS.
Effects of TMC-256C1 on HO-1 Expression in HT22 and BV2 Cells
To correlate the cytoprotective and anti-neuroinflammatory effects of TMC-256C1 with the induction of HO-1, we examined the effects of TMC-256C1 on HO-1 expression in HT22 and BV2 cells. Pre-treatment with TMC-256C1 at non-cytotoxic concentrations (10-40 μM) for 12 h dose-dependently increased HO-1 expression ( Figure 6A ,B) in HT22 and BV2 cells. The HO-1 inducer, cobalt protoporphyrin (CoPP) [27] was used as a positive control. The induction of HO-1 by TMC-256C1 reached a peak at 40 μM. At the concentration of 40 μM, HO-1 expression was first detected at 6 h, maximally increased at around 18 h, and then was gradually reduced after 24 h in HT22 and BV2 cells ( Figure 6C,D) . (10, 20 , and 40 µM) for 3 h, cells were treated with LPS for 1 h. Total proteins were prepared and Western blot analysis was performed using antibodies specific for IκB-α and p-IκB-α (A); Cytosolic and nuclear extracts were prepared for use in Western blots for NF-κB p65 and p50, using specific anti-p65 and anti-p50 monoclonal antibodies (B); A commercially available NF-κB ELISA (Active Motif) was used to test the nuclear extracts and determine the degree of NF-κB binding (C). Band intensity was quantified by densitometry and normalized to β-actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and proliferating cell nuclear antigen (PCNA), and the normalized values are presented at the bottom of each band. The data shown, representative of three independent experiments, are the mean values of three experiments˘SD. * p < 0.05 compared to the group treated with LPS.
To correlate the cytoprotective and anti-neuroinflammatory effects of TMC-256C1 with the induction of HO-1, we examined the effects of TMC-256C1 on HO-1 expression in HT22 and BV2 cells. Pre-treatment with TMC-256C1 at non-cytotoxic concentrations (10-40 µM) for 12 h dose-dependently increased HO-1 expression ( Figure 6A ,B) in HT22 and BV2 cells. The HO-1 inducer, cobalt protoporphyrin (CoPP) [27] was used as a positive control. The induction of HO-1 by TMC-256C1 reached a peak at 40 µM. At the concentration of 40 µM, HO-1 expression was first detected at 6 h, maximally increased at around 18 h, and then was gradually reduced after 24 h in HT22 and BV2 cells ( Figure 6C,D) . 
Effects of HO-1 Expression on Glutamate-Induced Oxidative Neurotoxicity and the Inhibition of Pro-Inflammatory Mediators by TMC-256C1
To confirm whether the cytoprotective effect of TMC-256C1 in HT22 cells and its anti-inflammatory effects in BV2 cells were mediated through the induction of HO-1 expression, the effect of SnPP, an inhibitor of HO-1, in TMC-256C1-treated cells was examined. HT22 cells were treated with 40 μM of TMC-256C1 for 12 h in the absence or presence of SnPP, and it was shown that SnPP significantly reversed the cytoprotective effect mediated by TMC-256C1 ( Figure 7A) . It was also shown that the induction of HO-1 expression by TMC-256C1 was necessary for suppressing the generation of glutamate-induced ROS ( Figure 7B) . Similarly, the potential correlation of HO-1 induction by TMC-256C1 with its anti-inflammatory effect was examined using SnPP. As shown in Figure 7C -G, pre-treatment with TMC-256C1 alone led to the inhibition of NO, PGE2, TNF-α, IL-6 and IL-12 production in LPS-stimulated cells. However, pre-treatment with both TMC-256C1 and SnPP partially reversed the inhibitory effects of TMC-256C1 on the production of those factors in LPS-stimulated cells. 
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Effects of TMC-256C1 on the Nuclear Translocation of Nrf2 in HT22 and BV2 Cells
Nuclear translocation of activated Nrf2 is an important upstream contributor to the transcription of HO-1 [28] . Therefore, we investigated whether treatment of HT22 and BV2 cells with TMC-256C1 induced nuclear translocation of Nrf2 to the cell nuclei. The cells were incubated with TMC-256C1 for 0.5, 1 and 1.5 h at a concentration of 40 μM, and the level of Nrf2 protein was then determined by western blot analysis. As shown in Figure 8A ,B, the protein levels of Nrf2 in the nuclear fractions of TMC-256C1-treated cells were gradually increased compared with those of the untreated cells, while they were concomitantly decreased in the cytoplasmic fractions. Moreover, the role of Nrf2 in HO-1 expression by TMC-256C1 was studied using siRNA against Nrf2. HT22 and BV2 cells were transiently transfected with siRNA Nrf2 and then were treated with TMC-256C1 for 12 h to induce HO-1 expression. As shown in Figure 8C ,D, Nrf2 siRNA have completely blocked off nuclear translocation of Nrf2. In addition, transient transfection with Nrf2 siRNA also abolishes induction of HO-1 expression by TMC-256C1 in both HT22 and BV2 cells. These results indicated that HO-1 induction upon incubation with TMC-256C1 is related to the Nrf2 nuclear translocation pathway in HT22 and BV2 cells.
Involvement of the Mitogen-Activated Protein Kinases (MAPK) Pathways in the Induction of HO-1 Expression by TMC-256C1
Mitogen-activated protein kinases (MAPK) is activated in response to oxidative stress and other various stress factors. It has been reported that the activation of the MAPK pathways are involved in the induction of HO-1 [29] . Therefore, to identify the signaling pathways involved in the induction of HO-1 expression by TMC-256C1, we analyzed its effects on the three MAPK pathways. The activation of these pathways was analyzed with activation-specific antibodies that selectively recognize the active and phosphorylated forms of extracellular signal-regulated kinases (ERK), c-Jun 
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Mitogen-activated protein kinases (MAPK) is activated in response to oxidative stress and other various stress factors. It has been reported that the activation of the MAPK pathways are involved in the induction of HO-1 [29] . Therefore, to identify the signaling pathways involved in the induction of HO-1 expression by TMC-256C1, we analyzed its effects on the three MAPK pathways. The activation of these pathways was analyzed with activation-specific antibodies that selectively recognize the active and phosphorylated forms of extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinase (JNK) , and p38. At the concentration of 40 µM, TMC-256C1 activated the p38 pathway by increasing the phosphorylation of p38 in both HT22 and BV2 cells. Phosphorylation of p38 was observed 15 min after the treatment of cells with TMC-256C1, and was sustained for 60 min (Figure 9 ). On the other hand, the phosphorylation of JNK and ERK was not observed. Furthermore, to confirm the role of p38 kinase in regulating the induction of HO-1 expression by TMC-256C1 in BV2 and HT22 cells, the effects of specific inhibitors of ERK (PD98059), JNK (SP600125) and p38 (SB203580) on the expression levels of HO-1 were examined by Western blot analysis (Figure 10) . The results indicated that HO-1 expression induced by TMC-256C1 was inhibited by the p38 inhibitor, whereas the JNK and ERK inhibitors had little or no effect on HO-1 protein levels. These results suggested that activation of the p38 pathway might be involved in the induction of HO-1 expression by TMC-256C1. N-terminal kinase (JNK) , and p38. At the concentration of 40 μM, TMC-256C1 activated the p38 pathway by increasing the phosphorylation of p38 in both HT22 and BV2 cells. Phosphorylation of p38 was observed 15 min after the treatment of cells with TMC-256C1, and was sustained for 60 min ( Figure 9 ). On the other hand, the phosphorylation of JNK and ERK was not observed. Furthermore, to confirm the role of p38 kinase in regulating the induction of HO-1 expression by TMC-256C1 in BV2 and HT22 cells, the effects of specific inhibitors of ERK (PD98059), JNK (SP600125) and p38 (SB203580) on the expression levels of HO-1 were examined by Western blot analysis (Figure 10 ). The results indicated that HO-1 expression induced by TMC-256C1 was inhibited by the p38 inhibitor, whereas the JNK and ERK inhibitors had little or no effect on HO-1 protein levels. These results suggested that activation of the p38 pathway might be involved in the induction of HO-1 expression by TMC-256C1. 
Involvement of the PI3K/Akt Pathway in the Induction of HO-1 Expression by TMC-256C1
There have been several studies showing that the PI3K/Akt pathway is involved in the induction of HO-1 expression by plant metabolites [30] [31] [32] . Therefore, additional analysis was conducted to 
There have been several studies showing that the PI3K/Akt pathway is involved in the induction of HO-1 expression by plant metabolites [30] [31] [32] . Therefore, additional analysis was conducted to correlate the induction of HO-1 by TMC-256C1 with the activity of the PI3K/Akt pathway. When the cells were treated with 40 µM of TMC-256C1, the phosphorylation levels of Akt in the cells gradually increased from 15 to 60 min ( Figure 11A,C) . Furthermore, pre-treatment of the cells with LY294002 (a specific inhibitor of PI3K) attenuated the induction of HO-1 expression by TMC-256C1 (Figure 11B,D) . These results suggested that TMC-256C1-induced expression of HO-1 was mediated through the PI3K/Akt pathway in HT22 and BV2 cells. 
Discussion
Oxidative stress and neuroinflammation are known to influence the etiology of many [33] . Therefore, searching for natural products with both anti-oxidative and anti-inflammatory activities could be a promising approach for the treatment of various neurodegenerative diseases, and several natural products have previously been identified as antioxidant and anti-inflammatory agents with their effects on the regulation of MAPK and HO-1 [34] [35] [36] [37] . 
Oxidative stress and neuroinflammation are known to influence the etiology of many [33] . Therefore, searching for natural products with both anti-oxidative and anti-inflammatory activities could be a promising approach for the treatment of various neurodegenerative diseases, and several natural products have previously been identified as antioxidant and anti-inflammatory agents with their effects on the regulation of MAPK and HO-1 [34] [35] [36] [37] .
In this study, it was shown that TMC-256C1 has a protective activity against glutamate-induced cytotoxicity in HT22 cells. TMC-256C1 suppressed glutamate-induced cell death and effectively inhibited the generation of ROS induced by glutamate in HT22 cells. Furthermore, it was demonstrated that the induction of HO-1 is closely related to the cytoprotective effect of TMC-256C1 against glutamate-induced oxidative stress in HT22 cells [38] . In this study, TMC-256C1 induced the expression of HO-1 in a dose-dependent manner, and this was necessary to suppress the generation of ROS by glutamate. Therefore, the cytoprotective effect of TMC-256C1 might be mediated through the induction of HO-1 expression.
Overproduction of inflammatory mediators by stimulated microglia may aggravate neuronal degeneration [39] . TMC-256C1 suppressed the gene expression of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-12 in BV2 cells treated with LPS. TMC256-C1 also suppressed the production of the inflammatory mediators such as NO and PGE 2 by down-regulating iNOS and COX-2 protein expression in the cells. NF-κB regulates the expression of a variety of genes including iNOS, COX-2, TNF-α, and IL-1β [40, 41] . With respect to this pathway, TMC256-C1 was found to inhibit the phosphorylation and degradation of IκB-α as well as the DNA-binding activity of NF-κB in LPS-stimulated BV2 cells, indicating the correlation of its anti-inflammatory effects with the inhibition of the activation of the NF-κB pathway in LPS-stimulated BV2 cells. TMC-256C1 also increased HO-1 expression and activity in BV2 cells in a dose-dependent manner. The correlation between the induction and activation of HO-1 and the resulting anti-inflammatory action in microglia has been reported [14, 16] . In a line with this, the inhibitory effects of TMC-256C1 on cell death and ROS production in glutamate-treated HT22 cells as well as the production of pro-inflammatory mediators and cytokines in LPS-stimulated BV2 cells were partially reversed by the treatment with SnPP, an inhibitor of HO-1 enzyme activity.
The Nrf2 transcription factor plays a crucial role in the expression of phase 2 detoxifying and antioxidant enzymes and in the activation of other inducible genes by various stimuli in response to oxidative stress [42] . Nrf2 is required for the expression of some inducible proteins including glutathione S-transferase, quinine reductase, and HO-1 [16] . In the present study, it was shown that TMC-256C1 promoted the translocation of Nrf2 into the nucleus, suggesting that Nrf2 may play an essential role in the induction of HO-1 expression by TMC-256C1. MAPK and PI3K/Akt and their associated signaling pathways are also involved in the regulation of HO-1 gene expression through the phosphorylation and activation of the Nrf2 pathway ( Figure 12 ) [43, 44] . In this study, the activation of the p38 and PI3K/Akt pathways appeared to be involved in the induction of HO-1 expression by TMC256-C1. In this study, it was shown that TMC-256C1 has a protective activity against glutamate-induced cytotoxicity in HT22 cells. TMC-256C1 suppressed glutamate-induced cell death and effectively inhibited the generation of ROS induced by glutamate in HT22 cells. Furthermore, it was demonstrated that the induction of HO-1 is closely related to the cytoprotective effect of TMC-256C1 against glutamate-induced oxidative stress in HT22 cells [38] . In this study, TMC-256C1 induced the expression of HO-1 in a dose-dependent manner, and this was necessary to suppress the generation of ROS by glutamate. Therefore, the cytoprotective effect of TMC-256C1 might be mediated through the induction of HO-1 expression.
Overproduction of inflammatory mediators by stimulated microglia may aggravate neuronal degeneration [39] . TMC-256C1 suppressed the gene expression of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-12 in BV2 cells treated with LPS. TMC256-C1 also suppressed the production of the inflammatory mediators such as NO and PGE2 by down-regulating iNOS and COX-2 protein expression in the cells. NF-κB regulates the expression of a variety of genes including iNOS, COX-2, TNF-α, and IL-1β [40, 41] . With respect to this pathway, TMC256-C1 was found to inhibit the phosphorylation and degradation of IκB-α as well as the DNA-binding activity of NF-κB in LPS-stimulated BV2 cells, indicating the correlation of its anti-inflammatory effects with the inhibition of the activation of the NF-κB pathway in LPS-stimulated BV2 cells. TMC-256C1 also increased HO-1 expression and activity in BV2 cells in a dose-dependent manner. The correlation between the induction and activation of HO-1 and the resulting anti-inflammatory action in microglia has been reported [14, 16] . In a line with this, the inhibitory effects of TMC-256C1 on cell death and ROS production in glutamate-treated HT22 cells as well as the production of pro-inflammatory mediators and cytokines in LPS-stimulated BV2 cells were partially reversed by the treatment with SnPP, an inhibitor of HO-1 enzyme activity.
The Nrf2 transcription factor plays a crucial role in the expression of phase 2 detoxifying and antioxidant enzymes and in the activation of other inducible genes by various stimuli in response to oxidative stress [42] . Nrf2 is required for the expression of some inducible proteins including glutathione S-transferase, quinine reductase, and HO-1 [16] . In the present study, it was shown that TMC-256C1 promoted the translocation of Nrf2 into the nucleus, suggesting that Nrf2 may play an essential role in the induction of HO-1 expression by TMC-256C1. MAPK and PI3K/Akt and their associated signaling pathways are also involved in the regulation of HO-1 gene expression through the phosphorylation and activation of the Nrf2 pathway ( Figure 12 ) [43, 44] . In this study, the activation of the p38 and PI3K/Akt pathways appeared to be involved in the induction of HO-1 expression by TMC256-C1. 
Cell Culture and Viability Assay
HT22 and BV2 cells were maintained at a density of 5ˆ10 5 cells/mL in DMEM medium with supplement, and were incubated according to the method described previously [45, 46] .
Quantitative Reverse-Transcription Polymerase Chain Reaction
Total RNA was isolated from the cells using Trizol (Invitrogen, Carlsbad, CA, USA), in accordance with the manufacturer's recommendations, and quantified spectrophotometrically at a wavelength of 260 nm. Total RNA (4 µg) was reverse-transcribed using a High Capacity RNA-to-cDNA kit (Applied Biosystems, Carlsbad, CA, USA). The cDNA was then amplified using a SYBR Premix Ex Taq kit (TaKaRa Bio Inc., Shiga, Japan) and a StepOnePlus Real-Time PCR system (Applied Biosystems). The primer sequences were as follows: 5 1 -CCA GAC CCT CAC ACT CAC AA-3 1 and 5 1 -ACA AGG TAC AAC CCA TCG GC-3 1 forward and reverse primers for TNF-α, 5 1 -AAT TGG TCA TAG CCC GCA CT-3 1 and 5 1 -AAG CAA TGT GCT GGT GCT TC-3 1 forward and reverse primers for IL-1β, 5 1 -TCA CAA GTC GGA GGC TT-3 1 and 5 1 -TGC AAG TGC ATC ATC GTT GT-3 1 forward and reverse primers for IL-6, and 5 1 -AGT GAC ATG TGG AAT GGC GT-3 1 and 5 1 -CAG TTC AAT GGG CAG GGT CT-3 1 forward and reverse primers for IL-12 [45] .
DNA-Binding Activity of NF-κB
The DNA-binding activity of NF-κB in nuclear extracts was measured using a TransAM kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer's instructions as described previously [47] .
Preparation of Cytosolic and Nuclear Fractions
Cells were homogenized (1:20, w/v) in PER-Mammalian Protein Extraction buffer (Pierce Biotechnology, Rockford, IL, USA) containing freshly added protease inhibitor cocktail I (EMD Biosciences, San Diego, CA, USA) and 1 mM phenyl methyl sulfonyl fluoride. The details of procedures for the preparation of nuclear and cytosolic fractions are described elsewhere [46] .
Nitrite (NO Production) and PGE 2 Determination
The production of nitrite in conditioned media was determined according to the method described previously [46] . Levels of PGE 2 present in each sample were determined using a commercially available kit from R&D Systems. The assay was performed according to the manufacturer's instructions as described previously [46] .
Western Blot Analysis
Cells were harvested by centrifugation at 200ˆg for 3 min. Subsequently, the cells were washed with phosphate buffered saline (PBS) and used by the radioimmunoprecipitation assay (RIPA) buffer containing 25 mM Tris-HCl buffer (pH 7.6) (Pierce Biotechnology, Rockford, IL, USA), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% SDS. The details of Western blot analysis are described elsewhere [45] .
Reactive Oxygen Species Measurement
The measurement of reactive oxygen species was determined according to the method described previously [48] . Briefly, HT22 cells (2.5ˆ10 4 cells/well in 24-well plates) were treated with 5 mM glutamate in the presence or absence of TMC-256C1 or SnPP (HO inhibitor) and incubated for 12 h [48] .
Statistical Analysis
The data are expressed as the mean˘standard deviation (SD) of at least 3 independent experiments. To compare three or more groups, one-way analysis of the variance was used, followed by Tukey's multiple comparison tests. The statistical analysis was performed with GraphPad Prism software, version 3.03 (GraphPad Software Inc., San Diego, CA, USA) [45] .
Conclusions
TMC-256C1, a metabolite isolated from the marine-derived fungus Aspergillus sp., was discovered to have neuroprotective and anti-neuroinflammatory effects. TMC-256C1 was originally identified as an inhibitor of IL-4 signal transduction [25] . However, the neuroprotective and anti-neuroinflammatory activities of this metabolite have not previously been reported. This study demonstrated that TMC-256C1 possesses these activities, and that they are mediated through the induction of HO-1 expression via the Nrf2 pathway. In addition, the PI3K/Akt and p38 pathways were suggested to be involved in activation of the Nrf2 pathway by TMC-256C1.
